Dana-Farber | sciencenewsnet.in

Study reveals factors influencing outcomes in advanced kidney cancer treated with immunotherapy

May 29, 2020 sarah Jonas ASCO, Dana-Farber, Dana-Farber Cancer Institute, Immunotherapy, Kidney Cancer, Nature Medicine

By analyzing tumors from patients treated with immunotherapy for advanced kidney cancer in three clinical trials, Dana-Farber Cancer Institute scientists have identified several features of the tumors that influence their response to immune checkpoint inhibitor drugs.

Announcement

Phyllis F. Cantor Center for Research in Nursing and Patient Care Services awarded two major research grants

May 26, 2020 sarah Jonas AACR, Dana-Farber, Dana-Farber Cancer Institute

Nurse-scientists from the Phyllis F. Cantor Center for Research in Nursing and Patient Care Services at Dana-Farber Cancer Institute received more than $1.3 million dollars in funding for two separate research projects.

Research Results

Immune system changes occur early in development of multiple myeloma, study finds

April 27, 2020 sarah Jonas Cancer, Dana-Farber, Dana-Farber Cancer Institute, Multiple Myeloma, smoldering myeloma

Long before multiple myeloma becomes a malignant disease, the collection of immune system cells and signal carriers amid the tumor cells undergoes dramatic shifts, with alterations in both the number and type of immune cells, researchers at Dana-Farber Cancer Institute, the Broad Institute of MIT and Harvard, and Massachusetts General Hospital (MGH) report in a new study.

Announcement

Dana-Farber Cancer Institute faculty recognized as 2020 ASCO leaders in cancer research and care

April 24, 2020 sarah Jonas Dana-Farber, Dana-Farber Cancer Institute

The American Society of Clinical Oncology (ASCO) recognized four Dana-Farber Cancer Institute researchers as winners of ASCO’s Special Awards, the Society’s highest honors. The recipients of these awards have worked to transform cancer care around the world.

Research Results

Novel targeted drug shows promise in advanced kidney cancer

February 13, 2020 sarah Jonas Dana-Farber, Dana-Farber Cancer Institute, Kidney Cancer

Scientists report promising activity of a novel drug that targets a key molecular driver of clear cell renal cell carcinoma (ccRCC) in patients with metastatic disease.

Research Results

Dozens of potential anti-cancer drugs netted in massive screening study

January 20, 2020 sarah Jonas 0 Comments Broad Institute of MIT and Harvard, Dana-Farber, Dana-Farber Cancer Institute, drug repurposing

A variety of existing drugs for treating conditions such as diabetes, inflammation, alcohol abuse, and arthritis in dogs can also kill cancer cells in the lab, according to a study by scientists at Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard.

Announcement

Dana-Farber Cancer Institute to Establish Chen-Huang Center for EGFR Mutant Lung Cancers

January 7, 2020 sarah Jonas 0 Comments Dana-Farber, Dana-Farber Cancer Institute, EGFR, Lung Cancer

Dana-Farber Cancer Institute will create the Chen-Huang Center for EGFR (epidermal growth factor receptor) Mutant Lung Cancers to stimulate research, promote clinical trials, and strengthen the Institute’s capabilities for studying and treating lung cancer.

Research Results

Dana-Farber scientists present promising findings in multiple myeloma at ASH Annual Meeting

December 9, 2019 sarah Jonas 0 Comments American Society Of Hematology, American Society of Hematology Annual Meeting, Dana-Farber, Dana-Farber Cancer Institute, Multiple Myeloma

Results of studies on a novel agent to treat multiple myeloma and a combination therapy aimed at slowing the progression of a precursor myeloma condition are among reports being presented by Dana-Farber Cancer Institute investigators at the ASH Annual Meeting.

Research Results

Use of venetoclax in reduced-intensity transplant conditioning regimen in patients with high-risk myeloid cancers shows promise in early trial

December 7, 2019 sarah Jonas 0 Comments American Society Of Hematology, American Society of Hematology Annual Meeting, AML acute myeloid leukemia, Dana-Farber, Dana-Farber Cancer Institute, Leukemia, Stem Cell Transplant

For patients with high-risk myeloid cancers undergoing a donor stem cell transplant, adding the targeted drug venetoclax to a reduced-intensity drug regimen prior to transplant is safe and does not impair the ability of the donor cells to take root in recipients’ bodies, a study led by Dana-Farber Cancer Institute researchers suggests.

Research Results

Genomic features of AML in patients over age 60 can predict success of bone marrow stem cell transplant, research shows

December 7, 2019 sarah Jonas 0 Comments American Society Of Hematology, American Society of Hematology Annual Meeting, AML acute myeloid leukemia, ASH annual meeting, Dana Farber Cancer Institute, Dana-Farber, Dana-Farber Cancer Institute, Stem Cell Transplant

For older patients with acute myeloid leukemia (AML), the prospects for success of a stem cell transplant can often be predicted based on the particular set of genetic mutations within the tumor cells, investigators at Dana-Farber Cancer Institute and other research centers will report today at the ASH Annual Meeting.